{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-034828","form_type":"8-K","ticker":"ANIX","cik":"0000715446","company_name":"Anixa Biosciences Inc","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.328592+00:00","generated_at":"2026-06-21T07:49:31.013178+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"medium","headline":"Anixa Biosciences reaches maximum tolerated dose in Phase 1a trial of breast cancer vaccine","bullets":["Maximum tolerated dose achieved in Phase 1a trial of preventative breast cancer vaccine.","Vaccine developed in collaboration with Cleveland Clinic.","Results presented at San Antonio Breast Cancer Symposium; press release and poster furnished."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-034828","json":"https://secwatch.observer/filing/0001493152-22-034828.json","markdown":"https://secwatch.observer/filing/0001493152-22-034828.md","text":"https://secwatch.observer/filing/0001493152-22-034828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/715446/000149315222034828/0001493152-22-034828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/715446/000149315222034828/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:49:31.013178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}